Eli Lilly 2012 Profit Forecast Misses Expectations


Salon Staff
January 5, 2012 6:36PM (UTC)

INDIANAPOLIS (AP) — Eli Lilly and Co. forecasts a steeper-than-expected earnings drop this year due to the expiration of a patent protecting its top-selling drug, the antipsychotic Zyprexa.

The Indianapolis drugmaker says it will earn between $3.10 and $3.20 per share in 2012. It expects Zyprexa revenue to plunge by over $3 billion. Zyprexa rang up more than $5 billion in 2010 sales. Its U.S. patent expired last fall, exposing it to cheaper generic competition.

Advertisement:

Lilly's forecast falls well short of analysts' expectations. They forecast earnings of $3.60 per share in the new year. The company's 2012 prediction would mean a drop of between 26 percent and 28 percent from its forecast for earnings of $4.30 to $4.35 per share in 2011.

Shares fell $1.36, or 3.3 percent, to $39.35 in pre-market trading.


Salon Staff

MORE FROM Salon Staff

BROWSE SALON.COM
COMPLETELY AD FREE,
FOR THE NEXT HOUR

Read Now, Pay Later - no upfront
registration for 1-Hour Access

Click Here
7-Day Access and Monthly
Subscriptions also available
No tracking or personal data collection
beyond name and email address

•••





Fearless journalism
in your inbox every day

Sign up for our free newsletter

• • •